Company Performance Metrics
- Anne Bousseau: Chief Medical OfficerPast Role: sanofi-aventis U.S, Oncology Project Director
- Hubert Mechain: Chief Technical & Manufacturing OfficerPast Role: BrainEver, Senior Manager CMC Operations
BrainEver’s innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including metabolism and epigenetic
stability.
BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.
Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS).
Beside Engrailed 1 in Parkinson Disease and ALS, BrainEver is currently generating a pipeline of 4 drug candidates targeting other neurodegenerative disease like Huntington Disease and Optic Neuropathies.
